Tags

Type your tag names separated by a space and hit enter

Effect of orlistat on cardiovascular disease risk in obese adults.
Diabetes Obes Metab. 2005 May; 7(3):254-62.DO

Abstract

AIM

The aim of this study is to compare the effect of orlistat vs. placebo on the predicted 10-year cardiovascular disease (CVD) risk in obese people with one or more cardiovascular risk factors treated for 12 months, in conjunction with a fat-reduced, but otherwise ad libitum, diet.

METHODS

A double-blind, randomized, placebo-controlled, parallel study was performed in conjunction with a fat-reduced diet and physical activity advice for 1 year. Participants (n = 339) from eight centres in Australia and New Zealand were randomized to either orlistat (120 mg) three times daily (n = 104 women, 66 men; mean +/- s.d. age = 52.0 +/- 7.5 years, body mass index (BMI) = 37.6 +/- 5.1 kg/m(2)) or placebo three times daily (n = 89 women, 80 men; age = 52.5 +/- 7.4 years, BMI = 38.0 +/- 4.9 kg/m(2)). The primary efficacy criterion was the 10-year risk of developing CVD calculated from the Framingham equation. Secondary efficacy criteria were body weight, waist circumference, blood pressure and serum concentrations of triglycerides, cholesterol (total, LDL and HDL), glucose, insulin and glycated haemoglobin and quality of life.

RESULTS

There was no difference in the change in 10-year CVD risk between orlistat and placebo groups over 1 year. The orlistat group, however, had significant favourable changes in many of the individual CVD risk factors (total cholesterol, LDL-cholesterol, glucose, glycated haemoglobin, insulin, body weight and waist circumference) and one of the domains of quality of life measured by means of the SF-36 questionnaire (vitality), compared to the placebo group. Significant reductions in medication use for hypertension and diabetes were observed in the orlistat group, compared to those in placebo, but there were no significant differences in medication use for blood lipids.

CONCLUSIONS

Orlistat may have reduced CVD risk, as judged by the favourable changes in individual risk factors and reductions in medication use, but the method used in order to measure absolute CVD risk in this study (Framingham CVD equation) was not sensitive enough to detect the changes in this relatively low-risk group (approximately 10% of risk of a CVD event over 10 years).

Authors+Show Affiliations

Department of Community Health, University of Auckland, Auckland, New Zealand. swinburn@deakin.edu.auNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15811142

Citation

Swinburn, B A., et al. "Effect of Orlistat On Cardiovascular Disease Risk in Obese Adults." Diabetes, Obesity & Metabolism, vol. 7, no. 3, 2005, pp. 254-62.
Swinburn BA, Carey D, Hills AP, et al. Effect of orlistat on cardiovascular disease risk in obese adults. Diabetes Obes Metab. 2005;7(3):254-62.
Swinburn, B. A., Carey, D., Hills, A. P., Hooper, M., Marks, S., Proietto, J., Strauss, B. J., Sullivan, D., Welborn, T. A., & Caterson, I. D. (2005). Effect of orlistat on cardiovascular disease risk in obese adults. Diabetes, Obesity & Metabolism, 7(3), 254-62.
Swinburn BA, et al. Effect of Orlistat On Cardiovascular Disease Risk in Obese Adults. Diabetes Obes Metab. 2005;7(3):254-62. PubMed PMID: 15811142.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of orlistat on cardiovascular disease risk in obese adults. AU - Swinburn,B A, AU - Carey,D, AU - Hills,A P, AU - Hooper,M, AU - Marks,S, AU - Proietto,J, AU - Strauss,B J, AU - Sullivan,D, AU - Welborn,T A, AU - Caterson,I D, PY - 2005/4/7/pubmed PY - 2005/7/19/medline PY - 2005/4/7/entrez SP - 254 EP - 62 JF - Diabetes, obesity & metabolism JO - Diabetes Obes Metab VL - 7 IS - 3 N2 - AIM: The aim of this study is to compare the effect of orlistat vs. placebo on the predicted 10-year cardiovascular disease (CVD) risk in obese people with one or more cardiovascular risk factors treated for 12 months, in conjunction with a fat-reduced, but otherwise ad libitum, diet. METHODS: A double-blind, randomized, placebo-controlled, parallel study was performed in conjunction with a fat-reduced diet and physical activity advice for 1 year. Participants (n = 339) from eight centres in Australia and New Zealand were randomized to either orlistat (120 mg) three times daily (n = 104 women, 66 men; mean +/- s.d. age = 52.0 +/- 7.5 years, body mass index (BMI) = 37.6 +/- 5.1 kg/m(2)) or placebo three times daily (n = 89 women, 80 men; age = 52.5 +/- 7.4 years, BMI = 38.0 +/- 4.9 kg/m(2)). The primary efficacy criterion was the 10-year risk of developing CVD calculated from the Framingham equation. Secondary efficacy criteria were body weight, waist circumference, blood pressure and serum concentrations of triglycerides, cholesterol (total, LDL and HDL), glucose, insulin and glycated haemoglobin and quality of life. RESULTS: There was no difference in the change in 10-year CVD risk between orlistat and placebo groups over 1 year. The orlistat group, however, had significant favourable changes in many of the individual CVD risk factors (total cholesterol, LDL-cholesterol, glucose, glycated haemoglobin, insulin, body weight and waist circumference) and one of the domains of quality of life measured by means of the SF-36 questionnaire (vitality), compared to the placebo group. Significant reductions in medication use for hypertension and diabetes were observed in the orlistat group, compared to those in placebo, but there were no significant differences in medication use for blood lipids. CONCLUSIONS: Orlistat may have reduced CVD risk, as judged by the favourable changes in individual risk factors and reductions in medication use, but the method used in order to measure absolute CVD risk in this study (Framingham CVD equation) was not sensitive enough to detect the changes in this relatively low-risk group (approximately 10% of risk of a CVD event over 10 years). SN - 1462-8902 UR - https://www.unboundmedicine.com/medline/citation/15811142/Effect_of_orlistat_on_cardiovascular_disease_risk_in_obese_adults_ L2 - https://doi.org/10.1111/j.1463-1326.2004.00467.x DB - PRIME DP - Unbound Medicine ER -